Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study
Lanreotide Autogel 120 mg (ATG120; Ipsen S.p.A, Milan, Italy) is a high-dose, sustained-release aqueous gel formulation, supplied in a prefilled syringe and given by deep subcutaneous injection. The aim of this study was to compare efficacy and tolerability of ATG120 given every 4-8 weeks with those...
Gespeichert in:
| Veröffentlicht in: | Clinical endocrinology (Oxford) 2007-10, Vol.67 (4), p.512-519 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 519 |
|---|---|
| container_issue | 4 |
| container_start_page | 512 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 67 |
| creator | Ronchi, C L Boschetti, M Degli Uberti, E C Mariotti, S Grottoli, S Loli, P Lombardi, G Tamburrano, G Arvigo, M Angeletti, G Boscani, P F Beck-Peccoz, P Arosio, M |
| description | Lanreotide Autogel 120 mg (ATG120; Ipsen S.p.A, Milan, Italy) is a high-dose, sustained-release aqueous gel formulation, supplied in a prefilled syringe and given by deep subcutaneous injection. The aim of this study was to compare efficacy and tolerability of ATG120 given every 4-8 weeks with those of octreotide LAR (o-LAR) given every 4 weeks. DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male). All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1). Then the interval between ATG120 injections was adjusted according to three different schemes: every 4, 6 or 8 weeks depending on GH levels (GH > 2.5 microg/l; 1 < GH |
| doi_str_mv | 10.1111/j.1365-2265.2007.02917.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68291383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68291383</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-a69e5ebf4da4d95036f58f49f52035cbe02dce05d3f77f599b312635c343e3db3</originalsourceid><addsrcrecordid>eNo1kN9O6zAMxnMB4v8roFwhJtHiNE27cjdNcM6RJiEhuJ7SxhlBaVOSFNgb8ljkaMw3tuSf_dkfIZRBzlLcvuWMVyIrikrkBUCdQ9GwOv86ICfAATKoqvKYnIbwBgBiDvUROWa1SMHYCfm-19p0sttSp6mkwbrPzKNFGZBq5_vJymjc8L9r5eDRRaOQXi-m6DZoZ5QVQPvNjJqBjonEIQb6aeIrlZ13PW6k3dLR44dxU0hl9Cgjqh3iurhfaN2wSSPRpLSXv14tnmZ3VCbxEYcbmm6JpksKfsebOCkzSEtDKrbn5FBLG_DiN5-Rl4f75-XfbPX4599yscpGxpuYyapBga0ulSxVI4BXWsx12WhRABddi1CoDkEorutai6ZpOSuq1OElR65afkaudntH794nDHHdm9ChTe5g-nFdzZP9fM4TePkLTm2Paj1600u_Xe-95z8TlYos</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68291383</pqid></control><display><type>article</type><title>Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ronchi, C L ; Boschetti, M ; Degli Uberti, E C ; Mariotti, S ; Grottoli, S ; Loli, P ; Lombardi, G ; Tamburrano, G ; Arvigo, M ; Angeletti, G ; Boscani, P F ; Beck-Peccoz, P ; Arosio, M</creator><creatorcontrib>Ronchi, C L ; Boschetti, M ; Degli Uberti, E C ; Mariotti, S ; Grottoli, S ; Loli, P ; Lombardi, G ; Tamburrano, G ; Arvigo, M ; Angeletti, G ; Boscani, P F ; Beck-Peccoz, P ; Arosio, M ; Italian Multicenter Autogel Study Group in Acromegaly</creatorcontrib><description><![CDATA[Lanreotide Autogel 120 mg (ATG120; Ipsen S.p.A, Milan, Italy) is a high-dose, sustained-release aqueous gel formulation, supplied in a prefilled syringe and given by deep subcutaneous injection. The aim of this study was to compare efficacy and tolerability of ATG120 given every 4-8 weeks with those of octreotide LAR (o-LAR) given every 4 weeks. DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male). All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1). Then the interval between ATG120 injections was adjusted according to three different schemes: every 4, 6 or 8 weeks depending on GH levels (GH > 2.5 microg/l; 1 < GH <or= 2.5 microg/l; GH <or= 1 microg/l, respectively). ATG120 was given for a further two to three doses, with a final assessment (Period 2) at Week 34, 36 or 42.
Hormonal (GH and IGF-I) and clinical efficacy and tolerability.
ATG120 induced a significant GH decrease from 9.9 +/- 11.3 at baseline (Visit 1) to 3.5 +/- 5.7 at the end of Period 1 (P < 0.01) and to 3.8 +/- 5.7 microg/l at the final visit (P < 0.01). IGF-I also decreased from 544 +/- 312 at baseline (Visit 1) to 318 +/- 181 at Period 1 and to 356 +/- 187 microg/l at the final visit (both P < 0.05 vs. baseline). The frequency of ATG120 administrations was adjusted to every 4 weeks in 12 patients, every 6 weeks in 4 patients and every 8 weeks in 6 patients; 1 patient withdrew before the dose adjustment. Serum GH and IGF-I achieved at the end of Period 1 and Period 2 were similar to those reached with o-LAR. The number of patients who achieved GH < 2.5 microg/l was comparable between o-LAR (43%) and ATG120 at Period 1 (48%) and at Period 2 (62%). Normal IGF-I levels were recorded in 8 patients during o-LAR (35%), 11 during ATG Period 1 (48%) and 10 at the final visit (43%). Last, 4 patients showed a better response to ATG120 and 2 to o-LAR.
Lanreotide Autogel 120 mg is an effective and well-tolerated therapy for acromegaly. In approximately half of patients ATG120 may be administered every 6-8 weeks, instead of every 4 weeks, without lost of efficacy.]]></description><identifier>ISSN: 0300-0664</identifier><identifier>DOI: 10.1111/j.1365-2265.2007.02917.x</identifier><identifier>PMID: 17555511</identifier><language>eng</language><publisher>England</publisher><subject>Acromegaly - blood ; Acromegaly - drug therapy ; Adult ; Aged ; Analysis of Variance ; Carrier Proteins - blood ; Delayed-Action Preparations - therapeutic use ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Glycoproteins - blood ; Growth Hormone - antagonists & inhibitors ; Growth Hormone - blood ; Humans ; Injections, Intramuscular ; Insulin Resistance ; Insulin-Like Growth Factor I - analysis ; Male ; Middle Aged ; Octreotide - therapeutic use ; Peptides, Cyclic - therapeutic use ; Prolactin - blood ; Somatostatin - analogs & derivatives ; Somatostatin - therapeutic use</subject><ispartof>Clinical endocrinology (Oxford), 2007-10, Vol.67 (4), p.512-519</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17555511$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ronchi, C L</creatorcontrib><creatorcontrib>Boschetti, M</creatorcontrib><creatorcontrib>Degli Uberti, E C</creatorcontrib><creatorcontrib>Mariotti, S</creatorcontrib><creatorcontrib>Grottoli, S</creatorcontrib><creatorcontrib>Loli, P</creatorcontrib><creatorcontrib>Lombardi, G</creatorcontrib><creatorcontrib>Tamburrano, G</creatorcontrib><creatorcontrib>Arvigo, M</creatorcontrib><creatorcontrib>Angeletti, G</creatorcontrib><creatorcontrib>Boscani, P F</creatorcontrib><creatorcontrib>Beck-Peccoz, P</creatorcontrib><creatorcontrib>Arosio, M</creatorcontrib><creatorcontrib>Italian Multicenter Autogel Study Group in Acromegaly</creatorcontrib><title>Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description><![CDATA[Lanreotide Autogel 120 mg (ATG120; Ipsen S.p.A, Milan, Italy) is a high-dose, sustained-release aqueous gel formulation, supplied in a prefilled syringe and given by deep subcutaneous injection. The aim of this study was to compare efficacy and tolerability of ATG120 given every 4-8 weeks with those of octreotide LAR (o-LAR) given every 4 weeks. DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male). All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1). Then the interval between ATG120 injections was adjusted according to three different schemes: every 4, 6 or 8 weeks depending on GH levels (GH > 2.5 microg/l; 1 < GH <or= 2.5 microg/l; GH <or= 1 microg/l, respectively). ATG120 was given for a further two to three doses, with a final assessment (Period 2) at Week 34, 36 or 42.
Hormonal (GH and IGF-I) and clinical efficacy and tolerability.
ATG120 induced a significant GH decrease from 9.9 +/- 11.3 at baseline (Visit 1) to 3.5 +/- 5.7 at the end of Period 1 (P < 0.01) and to 3.8 +/- 5.7 microg/l at the final visit (P < 0.01). IGF-I also decreased from 544 +/- 312 at baseline (Visit 1) to 318 +/- 181 at Period 1 and to 356 +/- 187 microg/l at the final visit (both P < 0.05 vs. baseline). The frequency of ATG120 administrations was adjusted to every 4 weeks in 12 patients, every 6 weeks in 4 patients and every 8 weeks in 6 patients; 1 patient withdrew before the dose adjustment. Serum GH and IGF-I achieved at the end of Period 1 and Period 2 were similar to those reached with o-LAR. The number of patients who achieved GH < 2.5 microg/l was comparable between o-LAR (43%) and ATG120 at Period 1 (48%) and at Period 2 (62%). Normal IGF-I levels were recorded in 8 patients during o-LAR (35%), 11 during ATG Period 1 (48%) and 10 at the final visit (43%). Last, 4 patients showed a better response to ATG120 and 2 to o-LAR.
Lanreotide Autogel 120 mg is an effective and well-tolerated therapy for acromegaly. In approximately half of patients ATG120 may be administered every 6-8 weeks, instead of every 4 weeks, without lost of efficacy.]]></description><subject>Acromegaly - blood</subject><subject>Acromegaly - drug therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Carrier Proteins - blood</subject><subject>Delayed-Action Preparations - therapeutic use</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glycoproteins - blood</subject><subject>Growth Hormone - antagonists & inhibitors</subject><subject>Growth Hormone - blood</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Insulin Resistance</subject><subject>Insulin-Like Growth Factor I - analysis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Octreotide - therapeutic use</subject><subject>Peptides, Cyclic - therapeutic use</subject><subject>Prolactin - blood</subject><subject>Somatostatin - analogs & derivatives</subject><subject>Somatostatin - therapeutic use</subject><issn>0300-0664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kN9O6zAMxnMB4v8roFwhJtHiNE27cjdNcM6RJiEhuJ7SxhlBaVOSFNgb8ljkaMw3tuSf_dkfIZRBzlLcvuWMVyIrikrkBUCdQ9GwOv86ICfAATKoqvKYnIbwBgBiDvUROWa1SMHYCfm-19p0sttSp6mkwbrPzKNFGZBq5_vJymjc8L9r5eDRRaOQXi-m6DZoZ5QVQPvNjJqBjonEIQb6aeIrlZ13PW6k3dLR44dxU0hl9Cgjqh3iurhfaN2wSSPRpLSXv14tnmZ3VCbxEYcbmm6JpksKfsebOCkzSEtDKrbn5FBLG_DiN5-Rl4f75-XfbPX4599yscpGxpuYyapBga0ulSxVI4BXWsx12WhRABddi1CoDkEorutai6ZpOSuq1OElR65afkaudntH794nDHHdm9ChTe5g-nFdzZP9fM4TePkLTm2Paj1600u_Xe-95z8TlYos</recordid><startdate>200710</startdate><enddate>200710</enddate><creator>Ronchi, C L</creator><creator>Boschetti, M</creator><creator>Degli Uberti, E C</creator><creator>Mariotti, S</creator><creator>Grottoli, S</creator><creator>Loli, P</creator><creator>Lombardi, G</creator><creator>Tamburrano, G</creator><creator>Arvigo, M</creator><creator>Angeletti, G</creator><creator>Boscani, P F</creator><creator>Beck-Peccoz, P</creator><creator>Arosio, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200710</creationdate><title>Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study</title><author>Ronchi, C L ; Boschetti, M ; Degli Uberti, E C ; Mariotti, S ; Grottoli, S ; Loli, P ; Lombardi, G ; Tamburrano, G ; Arvigo, M ; Angeletti, G ; Boscani, P F ; Beck-Peccoz, P ; Arosio, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-a69e5ebf4da4d95036f58f49f52035cbe02dce05d3f77f599b312635c343e3db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Acromegaly - blood</topic><topic>Acromegaly - drug therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Carrier Proteins - blood</topic><topic>Delayed-Action Preparations - therapeutic use</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glycoproteins - blood</topic><topic>Growth Hormone - antagonists & inhibitors</topic><topic>Growth Hormone - blood</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Insulin Resistance</topic><topic>Insulin-Like Growth Factor I - analysis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Octreotide - therapeutic use</topic><topic>Peptides, Cyclic - therapeutic use</topic><topic>Prolactin - blood</topic><topic>Somatostatin - analogs & derivatives</topic><topic>Somatostatin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ronchi, C L</creatorcontrib><creatorcontrib>Boschetti, M</creatorcontrib><creatorcontrib>Degli Uberti, E C</creatorcontrib><creatorcontrib>Mariotti, S</creatorcontrib><creatorcontrib>Grottoli, S</creatorcontrib><creatorcontrib>Loli, P</creatorcontrib><creatorcontrib>Lombardi, G</creatorcontrib><creatorcontrib>Tamburrano, G</creatorcontrib><creatorcontrib>Arvigo, M</creatorcontrib><creatorcontrib>Angeletti, G</creatorcontrib><creatorcontrib>Boscani, P F</creatorcontrib><creatorcontrib>Beck-Peccoz, P</creatorcontrib><creatorcontrib>Arosio, M</creatorcontrib><creatorcontrib>Italian Multicenter Autogel Study Group in Acromegaly</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ronchi, C L</au><au>Boschetti, M</au><au>Degli Uberti, E C</au><au>Mariotti, S</au><au>Grottoli, S</au><au>Loli, P</au><au>Lombardi, G</au><au>Tamburrano, G</au><au>Arvigo, M</au><au>Angeletti, G</au><au>Boscani, P F</au><au>Beck-Peccoz, P</au><au>Arosio, M</au><aucorp>Italian Multicenter Autogel Study Group in Acromegaly</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2007-10</date><risdate>2007</risdate><volume>67</volume><issue>4</issue><spage>512</spage><epage>519</epage><pages>512-519</pages><issn>0300-0664</issn><abstract><![CDATA[Lanreotide Autogel 120 mg (ATG120; Ipsen S.p.A, Milan, Italy) is a high-dose, sustained-release aqueous gel formulation, supplied in a prefilled syringe and given by deep subcutaneous injection. The aim of this study was to compare efficacy and tolerability of ATG120 given every 4-8 weeks with those of octreotide LAR (o-LAR) given every 4 weeks. DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male). All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1). Then the interval between ATG120 injections was adjusted according to three different schemes: every 4, 6 or 8 weeks depending on GH levels (GH > 2.5 microg/l; 1 < GH <or= 2.5 microg/l; GH <or= 1 microg/l, respectively). ATG120 was given for a further two to three doses, with a final assessment (Period 2) at Week 34, 36 or 42.
Hormonal (GH and IGF-I) and clinical efficacy and tolerability.
ATG120 induced a significant GH decrease from 9.9 +/- 11.3 at baseline (Visit 1) to 3.5 +/- 5.7 at the end of Period 1 (P < 0.01) and to 3.8 +/- 5.7 microg/l at the final visit (P < 0.01). IGF-I also decreased from 544 +/- 312 at baseline (Visit 1) to 318 +/- 181 at Period 1 and to 356 +/- 187 microg/l at the final visit (both P < 0.05 vs. baseline). The frequency of ATG120 administrations was adjusted to every 4 weeks in 12 patients, every 6 weeks in 4 patients and every 8 weeks in 6 patients; 1 patient withdrew before the dose adjustment. Serum GH and IGF-I achieved at the end of Period 1 and Period 2 were similar to those reached with o-LAR. The number of patients who achieved GH < 2.5 microg/l was comparable between o-LAR (43%) and ATG120 at Period 1 (48%) and at Period 2 (62%). Normal IGF-I levels were recorded in 8 patients during o-LAR (35%), 11 during ATG Period 1 (48%) and 10 at the final visit (43%). Last, 4 patients showed a better response to ATG120 and 2 to o-LAR.
Lanreotide Autogel 120 mg is an effective and well-tolerated therapy for acromegaly. In approximately half of patients ATG120 may be administered every 6-8 weeks, instead of every 4 weeks, without lost of efficacy.]]></abstract><cop>England</cop><pmid>17555511</pmid><doi>10.1111/j.1365-2265.2007.02917.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2007-10, Vol.67 (4), p.512-519 |
| issn | 0300-0664 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68291383 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Acromegaly - blood Acromegaly - drug therapy Adult Aged Analysis of Variance Carrier Proteins - blood Delayed-Action Preparations - therapeutic use Drug Administration Schedule Female Follow-Up Studies Glycoproteins - blood Growth Hormone - antagonists & inhibitors Growth Hormone - blood Humans Injections, Intramuscular Insulin Resistance Insulin-Like Growth Factor I - analysis Male Middle Aged Octreotide - therapeutic use Peptides, Cyclic - therapeutic use Prolactin - blood Somatostatin - analogs & derivatives Somatostatin - therapeutic use |
| title | Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A09%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20a%20slow-release%20formulation%20of%20lanreotide%20(Autogel)%20120%20mg)%20in%20patients%20with%20acromegaly%20previously%20treated%20with%20octreotide%20long%20acting%20release%20(LAR):%20an%20open,%20multicentre%20longitudinal%20study&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Ronchi,%20C%20L&rft.aucorp=Italian%20Multicenter%20Autogel%20Study%20Group%20in%20Acromegaly&rft.date=2007-10&rft.volume=67&rft.issue=4&rft.spage=512&rft.epage=519&rft.pages=512-519&rft.issn=0300-0664&rft_id=info:doi/10.1111/j.1365-2265.2007.02917.x&rft_dat=%3Cproquest_pubme%3E68291383%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68291383&rft_id=info:pmid/17555511&rfr_iscdi=true |